Document:

EX-10.10

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS
MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

Exhibit 10.10 
 AMENDMENT
1 TO LICENSE AGREEMENT 
 This Amendment (“Amendment”) to the License Agreement is made and entered into as of the date of the
last signature on the signature page below (the “Effective Date of Amendment”), by and between JCR Pharmaceuticals Co. Ltd., a Japanese corporation (“JCR”), and Osiris Acquisition II, Inc., doing business as Osiris
Therapeutics, Inc., a Delaware corporation (“OSIRIS”), with reference to the following background: 
 BACKGROUND 

WHEREAS, JCR and OSIRIS are Parties to a License Agreement, dated August 26, 2003 (the “License Agreement”; capitalized terms
used herein and not otherwise defined shall have the meanings ascribed to them in the License Agreement); and 
 WHEREAS, JCR and OSIRIS
have determined that it is desirable to amend and restate certain provisions of the License Agreement as set forth herein, and incorporate additional provisions to the License Agreement, more particularly for the purpose of expanding the
Field as set forth herein, to reflect further agreements between them. 
 NOW, THEREFORE, the Parties hereto, intending to be legally
bound, and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, hereby agree as follows: 
  

	1.	Amended Definitions: The following Definitions shall be amended: 

 Amended
Section 1.6. Section 1.6 of the License Agreement is hereby amended and restated in its entirety to read as follows: “Field” shall mean the use of (a) MSC in or in conjunction with the treatment of hematological
malignancies by the use of hematopoietic stem cells derived from peripheral blood, cord blood or bone marrow (“Field 1”) and (b) MSC to derive hepatocytes for use in non-clinical drug screening and evaluation
(“Field 2”). 
  

	2.	Amendment to Section 2.1(a): Section 2.1(a) shall be amended and restated as follows: 

2.1(a) OSIRIS hereby grants to JCR and its Affiliates an exclusive royalty-bearing license in the Territory, with the right to grant
sublicenses in accordance with the terms of this Agreement as provided in Section 2.2, under the OSIRIS Patents and OSIRIS Technology to develop, register and to obtain Product Registrations, use, make, have made, import, export, offer to sell,
sell and have sold Products for use in the Field 1 in the Territory. OSIRIS hereby further grants to JCR and its Affiliates a non-exclusive license in the Territory, with the right to grant sublicenses in accordance with the terms of this
Agreement as provided in Section 2.2, under the OSIRIS Patents and OSIRIS Technology to develop, register and to obtain product registrations, use, make, have made, import, export, offer to sell, sell and have sold MSCs for use in Field 2
in the Territory. 
 Notwithstanding the foregoing, the right to make and have made MSCs for use in the Field 2 is restricted to JCR.

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS
MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
  

	3.	Certain Provisions of License Agreement. Sections 3.1, 3.2, 3.3, 3.4, 4.1, 4.2, 4.3, and 4.4 shall only apply to Products in Field 1. 

 

	4.	New Section. The following new Section shall be added to Article 4: 

 4.5
Profit Share for Products in Field 2. Osiris and JCR will share Net Profits of MSC sold by JCR or its Sublicensees for use in Field 2 as follows: [* * *] to OSIRIS and [* * *] to JCR; notwithstanding the foregoing, in the event that
Osiris’ [* * *] profit share is equal to less than [* * *] of Net Sales, then JCR shall remit the difference to Osiris. The Net Profit shall be equal to: (i) Net Sales of MSC for use in Field 2 less (ii) Cost of Goods for MSC for
use in Field 2. “Cost of Goods” shall mean the actual cost of producing, processing and packaging MSC for use in Field 2, including related quality assurance and quality control activities required by applicable law, which
actual cost is comprised of cost of goods as determined in accordance with Japanese GAAP employed by JCR, and shall include direct labor, direct material, the allocable portion of the manufacturing overhead directly attributable to such MSC and
administrative cost. 
 4.6 Diligence by JCR’s Sublicensees. For the sale of MSCs for use in Field 2, JCR
shall cause its Sublicensees to exercise reasonable diligence to use MSC only for applications within Field 2. 
  

	5.	Amendment of Article 6. The following Sections shall be amended and restated as follows: 

6.1 Payments. All royalty payments and Net Profit share due hereunder shall be paid quarterly within sixty
(60) days of the end of each calendar quarter. Each such payment shall be accompanied by a statement detailing the Cost of Goods of Product or MSC in Field 2, the amount of gross sales of Product or MSC, the calculation of Net Sales, the
calculation of Net Profits, the number units of Product or MSC sold during such quarter, the amount of royalties due on such Net Sales of Product or MSC for Field 1, the amount of Net Profit due for such quarter, the conversion rates used in
converting to United States Dollars and any other information reasonably requested by OSIRIS to enable OSIRIS to determine amounts owed hereunder. 

6.2 Mode of Payment. JCR shall make all payments required under this Agreement as directed by OSIRIS from time to time
in United States Dollars. Whenever for the purpose of calculating royalties or Net Profit share conversion from foreign currency shall be required, such conversion shall be at the rate of exchange of the last business day of the applicable calendar
quarter as published in the Wall Street Journal, New York edition. 
 6.3 Records Retention. JCR and its Affiliates
and its Sublicensees and co-marketers shall keep complete and accurate records pertaining to the manufacture and sale of Products or MSCs in the Territory and covering all transactions from which Net Sales and Net Profits are derived for a period of
three calendar years after the year in which such sales occurred, and in sufficient detail to permit OSIRIS to confirm the accuracy of royalty payments or Net Profit share due hereunder. 

  
 -2- 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS
MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

6.4 Audit Request. At the request and expense (except as provided below) of OSIRIS, JCR and its Affiliates and its
Sublicensees and co-marketers shall permit an independent certified public accountant appointed by OSIRIS and reasonably acceptable to JCR, at reasonable times and upon reasonable notice, to examine those records and all other material documents
relating to or relevant to Net Sales or Net Profits in the possession or control of JCR and/or its Affiliates or its Sublicensees and co-marketers, for a period of three years after such royalties or Net Profit share have accrued. Said accountant
shall not disclose to OSIRIS any information other than information relating to said reports, royalties, and payments. If, as a result of any inspection of the books and records of JCR or its Affiliates or its Sublicensees and co-marketers it is
shown that JCR’s royalty payments or Net Profit share under this Agreement were less than the amount which should have been paid, then JCR shall make all payments required to be made to eliminate any discrepancy revealed by said inspection
within forty-five (45) days after OSIRIS’ demand therefore. Furthermore if the royalty payments or Net Profit share was less than the amount which should have been paid by an amount in excess of five percent (5%) of the royalty
payments or Net Profit share actually made during the period in question, JCR shall also reimburse OSIRIS for the cost of such inspection. 
  

	6.	Continuing Effect. Except as specifically modified by this Amendment, all of the provisions of the License Agreement are hereby ratified and confirmed to be in full force and effect, and shall remain in full
force and effect. 

  

	7.	Entire Agreement; Successors and Assigns. The License Agreement, this Amendment, and any written agreements executed by both Parties pertaining to the subject matter therein, constitute the entire agreement
between the Parties hereto with respect to subject matter hereof and thereof. Said documents supersede all other agreements and understandings between the Parties with respect to the subject matter hereof and thereof, whether written or oral. If
there is a conflict between the provisions of the License Agreement and this Amendment, this Amendment shall govern. This Amendment may be amended only by a written instrument executed by each of the Parties. This Amendment shall be binding upon and
shall inure to the benefit of the Parties and their respective heirs, administrators, executors, affiliates, successors and permitted assigns. 

  

	8.	Headings. The section headings contained in this Amendment are for reference purposes only and shall not affect in any way the meaning or interpretation of the Amendment. 

 

	9.	Counterparts. This Amendment may be executed in one or more counterparts, all of which shall be considered one and the same agreement, and shall become a binding agreement when one or more counterparts have been
signed by each Party and delivered to the other Party. 

  

	10.	Governing Law. This Amendment shall be governed by the laws of the State of Maryland, USA, without regard to its choice of law principles. 

 

	11.	 Arbitration. All disputes, controversies, or differences which may arise between the Parties, out of or in relation to or in connection with
this Amendment, or the breach thereof, shall be 

  
 -3- 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS
MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

	 	
finally settled by arbitration pursuant to the Japan-American Trade Arbitration Agreement, of September 16, 1952, by which each Party hereto is bound. The place of arbitration shall be the
country of the proposed defendant. Where the defendant in such arbitration is JCR, arbitration shall be held in Osaka, Japan, and shall be conducted in accordance with the arbitration rules of the Japan Commercial Arbitration Association. Where the
defendant in such arbitration is OSIRIS, arbitration shall be held in Maryland, United States of America, and shall be conducted under the arbitration rules of the American Arbitration Association. This Amendment shall be interpreted and governed
by, and all differences of opinion which may rise in the signing, implementation or termination of this Amendment shall be adjudicated according to the laws of the State of Maryland, United States of America, if JCR is the plaintiff and OSIRIS is
the defendant, and by the laws of Japan, if OSIRIS is the plaintiff and JCR is the defendant. 

 [Signatures appear on
following page] 

  
 -4- 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS
MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

IN WITNESS WHEREOF, each of the Parties has caused this Amendment to be executed as of the date hereof by a duly authorized corporate officer.

  

			
	[OSIRIS]
		
	By:		 /s/ Cary J. Claiborne

	Name:		Cary J. Claiborne
	Title:		CFO
	Date:		6/20/05
	
	JCR PHARMACEUTICALS, CO., LTD.
		
	By:		 /s/ Shin Ashida

	Name:		Shin Ashida
	Title:		President and Chief Executive Officer
	Date:		6/27/05EX-10.11

 Exhibit 10.11 

OSIR001 3/24/93 
 (002) 

TECHNOLOGY TRANSFER, AND LICENSE AGREEMENT 

Between 
 CASE WESTERN
RESERVE UNIVERSITY 
 and 

OSIRIS THERAPEUTICS, INC. 

This agreement, effective as of the 1st day of January, 1993 (“Effective
Date”), is between OSIRIS THERAPEUTICS, Inc., corporation domiciled in the State of Ohio having an address at 11000 Cedar Avenue, Cleveland, OH 44106 (“OSIRIS”), and Case Western Reserve University, an Ohio non-profit corporation
having its principal office at 2040 Adelbert Road, Cleveland, Ohio (“CWRU”). 
 BACKGROUND 

CWRU, with principal activities in teaching and scholarship, makes its capabilities available to commercial entities for research to the
extent that it complements and does not conflict with CWRU’s principal activities. In this spirit, CWRU is prepared to continue its development relationship with OSIRIS (a company created to commercialize the mesenchymal stem cell technology)
and to license the Technology, as that item is defined in Article X below, including that established by Dr. Arnold I. Caplan while working as a full-time professor at CWRU. This license transfers the state-of-the-art of the
mesenchymal stem cell technology to OSIRIS, according to the terms and conditions set forth below. This state-of-the-art includes patents and know-how. Future patents based on this know-how will be made in the name of CWRU and will be covered by the
royalty agreement stated herein if substantially invented at CWRU in the future. 
 AGREEMENT 

ARTICLE I: LICENSE 
 1.1
Grant and Subject Matter. CWRU grants OSIRIS a sole and exclusive worldwide License, under Technology, Existing Patent Rights (to the extent not owned by OSIRIS) and Developed Patent Rights (“License”) to make, have made, use and
sell Product and Process (terms defined in Section 10), including the right to grant sublicenses. 
 1.2 Term of Agreement. This
Agreement shall be in full force and effect from the date first set forth above and shall remain in effect for twenty-five (25) years or until all patents issued in all countries in accordance with this License hereunder have expired or until
otherwise terminated by operation of law, whichever is last to occur, or by the acts of the parties in accordance with the terms of this Agreement. 

 1.3 Retained Rights. CWRU will retain a royalty-free right to use the Technology and
patent rights of the License for any nonclinical research, testing or educational purpose of CWRU. In no event shall CWRU have any right to use the Technology or the patent rights of the License for any commercial purpose whatsoever. In addition,
the License will be subject to such rights as are required to be accorded to any governmental agency as a consequence of prior or contemporaneous funding for research or development of the subject matter of the License. 

1.4 Sublicenses. OSIRIS agrees to forward to CWRU a copy of any and all fully executed sublicense agreements, and further agrees to
forward annually a copy of such reports received by OSIRIS from its sublicensees during the preceding twelve (12) month period under the sublicenses as shall be pertinent to a royalty accounting to CWRU under said sublicense agreement. 

1.5 The license granted under Existing Patent Rights is royalty-free. 

1.6 The license granted under Developed Patent Rights is royalty-bearing as provided in Paragraph 6.2. 

ARTICLE II: TITLE 
 Except
as provided in Section 3.1, CWRU shall retain title to the subject matter of the License. 
 ARTICLE III: PATENTS 

3.1 To the extent permitted by existing obligations, CWRU hereby assigns all right, title and interest in and to Existing Patent Rights to
OSIRIS. OSIRIS shall bear all responsibility for, and shall take all actions in connection with, the prosecution of the Existing Patent Rights. CWRU shall cooperate with OSIRIS with respect to such prosecutions. 

3.2 New Applications. CWRU shall own all Developed Patent Rights. In the event either party hereto believes a patent application should
be filed with respect to the Technology, such party shall notify the other party hereto. If OSIRIS fails to file such application within sixty (60) days after the date of such notice, CWRU shall have the right to file the application in its own
name, at its own expense; provided, however, that CWRU’s application must be filed within six (6) months after the expiration of OSIRIS’ sixty (60) day filing period. 

If CWRU does not file within such six-month period, CWRU must give a new notice to OSIRIS, and the process described above must be repeated in
its entirety, before CWRU shall have the right to file such application. 
 3.3 OSIRIS shall own any patent application which is directed to
an invention made by an employee of OSIRIS or by an Investigator when the Investigator is working on the premises of OSIRIS. 
 3.4
Cost. OSIRIS will pay the cost of all patent applications filed by it pursuant to Section 3.2. 

  
 2 

 3.5 Reports. The party filing the patent application pursuant to Section 3.2 above
shall keep the other informed in a timely manner of the status of the application. 
 3.6 Infringement. Each party shall promptly
notify the other party if it becomes aware of any infringement of any patents licensed as part of this Agreement. Neither OSIRIS nor CWRU shall have any obligation to initiate litigation to protect any patent or proprietary right granted under this
Agreement. However, each party will have the unqualified right to initiate legal action, or to fully participate in any legal action initiated by the other party, to protect its interests. In any litigation, each party and their respective attorneys
will cooperate with the other party. If OSIRIS elects to institute suit against any third party to protect any patent or proprietary rights granted under this Agreement, fifty percent (50%) of associated costs (including reasonable
attorneys’ fees) which have been paid by OSIRIS may be offset against royalties owed to CWRU pursuant to Article VI, but such offsetting shall not exceed fifty percent (50%) of the total royalties owed to CWRU. All damages awarded in
any suit will belong exclusively to the party initiating the suit, except that the amounts offset pursuant to this Section 3.6 will be reimbursed to CWRU from damages awarded to OSIRIS after OSIRIS’s own legal costs have been reimbursed.

 3.7 In the event that litigation against OSIRIS is initiated by a third-party charging OSIRIS with infringement of a patent of the third
party as a result of the manufacture, use or sale by OSIRIS of Product or Process for which royalties are due to CWRU hereunder, OSIRIS shall promptly notify CWRU in writing thereof. OSIRIS’s costs as to any such defense shall be creditable
against any and all payments due and payable to CWRU under Article VI of this Agreement but no royalty payment after taking into consideration any such credit shall be reduced by more than 50%. 

ARTICLE IV: CONFIDENTIALITY 

4.1 Confidentiality. CWRU and OSIRIS agree to advise their respective employees that it is necessary to hold in confidence all
information received from the other party in connection with the License (“Information”) for a period of two years following disclosure. The receiving party will use reasonable efforts to prevent disclosure of such Information during such
period. This Section 4.1 shall not apply, however, to Information which: 
 (i) is now in or shall enter the public domain as the
result of its disclosure in a publication, the issuance of a patent or otherwise without the legal fault of the receiving party; 
 (ii) the
receiving party can prove was in its possession in written form at the time of disclosure by the other party; or 
 (iii) comes into the
hands of the receiving party by means of a third party who is entitled to make such disclosure and who has no obligation of confidentiality toward the disclosing party. 

(iv) where disclosure is required under any applicable ruling, regulation or law, including but not limited to regulatory filings. 

(v) where disclosure is made through the filing of a patent application. 

  
 3 

 Notwithstanding the foregoing, OSIRIS can disclose information to a third party under an
obligation of confidentiality similar to the obligation of confidentiality under this agreement. 
 4.2 Remedies. Each party shall be
entitled to injunctive relief if there is a threat that Information that is the subject matter of the License will be disclosed by the other party contrary to the terms of this agreement. Each party shall notify the other party in writing of any
proposed release of Information thirty (30) days prior to release of such Information. The party receiving such notice will have thirty (30) days to review the materials and shall not unreasonably withhold permission for the Information to
be released. 
 4.3 (a) During the period in which OSIRIS holds a license, CWRU and Investigators (as defined in Paragraph 10.9) shall not,
without OSIRIS’ prior written approval, distribute or allow Material (as defined in Paragraph 10.8) to be distributed to for-profit entities or persons known to be employed thereby or consulting or performing research therefor. 

(b) CWRU and Principal Investigator (as defined in Paragraph 10.7) shall have the right to transfer Material to not-for-profit entities or
persons known to be affiliated therewith provided that such entities or persons sign a material transfer agreement mutually agreed to by the parties to this Agreement. 

(c) Prior to any such distribution of any such Material, CWRU and OSIRIS shall use best efforts to consider the patentability of such Material
and cooperate to file, where appropriate, a patent application for such Material prior to its distribution, in accordance with Article III of this Agreement. 

ARTICLE V: PUBLICATION 

CWRU will provide OSIRIS with a copy of any proposed publication relating to the Technology thirty (30) days prior to their submission
for publication. OSIRIS will have thirty (30) days from the date of receipt of each such proposed publication to review the materials. Upon receipt within the thirty-day (30) period of a written notice from OSIRIS identifying those
portions of the proposed publication for which it wishes publication delayed, CWRU will use its best efforts either to cause the materials identified to be deleted or to cause publication to be delayed for ninety (90) days . 

ARTICLE VI: ROYALTIES, CONSIDERATION AND PAYMENTS 

6.1 Payment. OSIRIS agrees to pay to CWRU an amount equal to $83,061 for the licenses and rights granted under this Agreement and for
the filing and prosecution of Existing Patent Rights. Such amount shall be paid within thirty (30) days of the initial financing of OSIRIS, which financing shall be in an amount of at least $2,000,000, (“Initial Capitalization”). 

6.2 Royalties. As consideration for the License, OSIRIS will pay CWRU a royalty on all Product or Process providing that such Product or
Process where sold is covered by a claim of a granted patent which is a Developed Patent Right licensed under this Agreement (“Royalty Bearing Product”) as follows. 

  
 4 

 (i) Three percent (3%) of the Net Sales of Royalty Bearing Products sold by OSIRIS; and

 (ii) Twenty-five percent (25%) of the royalties received by OSIRIS from its SUBLICENSEES’ sales of a Royalty Bearing Product.

 Provided, however, that with respect to each Royalty Bearing Product covered under either (I) or (ii) above, no royalty shall
be payable for the first three years in which such Royalty Bearing Product is sold. Net Sales shall be defined as the amount received from sales of all Royalty Bearing Products less discounts, returns, transportation costs, insurance costs and taxes
of any kind whatsoever. 
 6.3 Royalty Payments. (a) Royalties due will be paid to CWRU every year for the term of this Agreement
on the 31st of March, and shall be calculated according to the Net Sales of all Royalty Bearing Products during the calendar year immediately preceding the year in which such royalty payments are due. Each royalty payment shall be accompanied by an
accounting showing the calculation of net sales for the calendar year in question. 
 6.4 In the event that royalties are to be paid by
OSIRIS to a party who is not an Affiliate of OSIRIS for Royalty Bearing Product (“Other Royalties”), for which royalties are also due to CWRU pursuant to Paragraph 6.2 then the royalties to be paid to CWRU by OSIRIS pursuant to Paragraph
6.2 shall be reduced by 50% of the amount of such Other Royalties, but in no event shall any royalties under Paragraph 6.2 be reduced by more than fifty percent (50%) . 

6.5 Equity Interest to CWRU. CWRU will be sold 1,200 shares of OSIRIS’ Common Stock based on the Founders’ capitalization in
Appendix A. The Initial Capitalization shall mean the first capitalization of the company in which the total capital contribution is at least two million dollars. The selling price shall be $0.10 per share. The shares will be sold in accordance with
a Restricted Stock Purchase Agreement which contains terms among others that prior to an initial public offering OSIRIS or its designee will have a right of first refusal with respect to a any transfer of the shares; and that the shares will be
subject to underwriter “lock-up” restrictions in any underwritten offering. 
 6.6 Foreign currency conversions. When
royalties accrue for currencies other than United States dollars, payment to CWRU shall be in United States dollars converted from that foreign currency at the average of the rates established by BankAmerica for that foreign currency on the last
business day of each month of the calendar year which ended immediately preceding the day on which OSIRIS pays such royalties to CWRU. 
 6.7
Audit Rights. CWRU has the right to inspect any books or records of OSIRIS containing information which may be reasonably necessary for the purpose of verifying the royalties payable to CWRU This inspection is to be made by an independent
certified public accountant of CWRU’s choice to whom OSIRIS has no reasonable objection. The inspection is to be done at the expense of CWRU, upon reasonable notice, during normal business hours and no more than once per year. 

  
 5 

 6.8 Initial Capitalization. If, by December 31, 1993, OSIRIS has not received funding
of at least $2 million ($2,000,000), this Agreement shall terminate, unless extended by mutual agreement and OSIRIS shall, at its sole expense, transfer to CWRU all right, title and interest in the Existing Patent Rights. 

6.9 Minimum Performance. If, after the sixth anniversary of the initial capitalization of OSIRIS, payments due to CWRU under
Article VI fall below fifty thousand dollars ($50,000) per year, the License granted by this Agreement shall be terminated unless OSIRIS pays CWRU the difference between the amount due and fifty thousand dollars ($50,000), unless extended by
mutual agreement. 
 ARTICLE VII: BREACH AND TERMINATION 

7.1 Breach. If either party at any time commits any material breach of the Agreement and fails to remedy it within thirty (30) days
after receiving written notice of the breach or such additional time as may be reasonably required to effect the cure so long as the curing party is continuing to diligently pursue its efforts to cure, the aggrieved party may, at its option, cancel
this Agreement by notifying the other in writing. This remedy is in addition to any other remedies to which it may be entitled. Any failure to cancel this Agreement for any breach will not constitute a waiver by the aggrieved party of its right to
cancel this Agreement for any other breach whether similar or dissimilar in nature. 
 7.2 Bankruptcy. CWRU may terminate this
Agreement if OSIRIS files or has filed against it a petition in bankruptcy which is not dismissed within thirty (30) days, or files an assignment for benefit of creditors, or if a receiver is appointed for all or part of its assets, or if it
petitions for or consents to any relief under any applicable insolvency, moratorium or similar statute. All rights and licenses granted to OSIRIS under or pursuant to this Agreement are, and shall otherwise be deemed to be, for purposes of
Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101(60) of the Bankruptcy Code. The parties hereto agree that so long as OSIRIS, as a licensee of such rights
under this Agreement, shall continue to perform all obligations under this Agreement, including but not limited to the making of timely royalty payments, OSIRIS shall retain and may fully exercise all of its rights and elections under the Bankruptcy
Code, and pursuant to Section 365(n), OSIRIS shall have the right to receive all current embodiments of the licensed intellectual property. The parties hereto further agree that, in the event that CWRU files or has filed against it a petition
in bankruptcy which is not dismissed within thirty (30) days, or files an assignment for benefit of creditors, or if a receiver is appointed for all or part of its assets, or if it petitions for or consents to any relief under any applicable
insolvency, moratorium or similar statue, OSIRIS shall have the right to retain and enforce its rights under this Agreement with respect to the Technology, Existing Patent Rights and Developed Patent Rights. 

7.3 Force Majeure. Each of the parties will be excused from performance of this Agreement only to the extent that performance is
prevented by conditions beyond the reasonable control of the party affected. The parties will, however, use their best efforts to avoid or cure such conditions. The party claiming such conditions as an excuse for delaying performance will give
prompt written notice of the conditions, and its intent to delay performance, to the other party and will resume its performance as soon as performance is possible. 

  
 6 

 7.4 Effect of Termination. OSIRIS’ License shall terminate simultaneously with any
termination of this Agreement. Except as provided in Section 6.8 above, expiration, cancellation or termination of this Agreement will not affect any previously vested or accrued rights of either party under this Agreement. Upon termination of
this Agreement by either party, in whole or as to any specified patent or any claim of such patent, OSIRIS shall provide CWRU with a written inventory of all products affected by such termination in process of manufacture, in use or in stock and
shall request each sublicensee to provide such written inventory. OSIRIS and its sublicensees shall have the right to sell off such inventory unless OSIRIS is the subject of a pending or threatened product liability claim. 

7.5 Effect of termination of this Agreement on sublicenses. Any sublicense granted by OSIRIS under this Agreement shall provide for
automatic assignment to CWRU of OSIRIS interest therein upon termination of this Agreement. CWRU agrees to accept such assignment and the sublicense shall remain in full force and effect as a direct license from CWRU in accordance with the terms and
conditions thereof. CWRU agrees to confirm in writing its obligations under this Paragraph to a sublicensee at the request of OSIRIS. 
 7.6
Termination. OSIRIS shall have the right to terminate this Agreement or any of the licenses granted hereunder in any country upon providing CWRU with sixty (60) days prior written notice. 

ARTICLE VIII: REPRESENTATIONS AND WARRANTIES 

8.1 Agreements. Each party represents that, to the best of its knowledge, this Agreement does not violate any of its prior commitments
or agreements. 
 8.2 Claims. Each party represents that, to the best of its knowledge, there are no legal actions, pending or
threatened, which would question this Agreement or the right of either party to perform its obligations under this Agreement. 
 8.3
Authorization by CWRU. CWRU warrants that execution and performance of this Agreement have been duly authorized by all necessary corporate actions. 

8.4 Authorization by OSIRIS. OSIRIS warrants that execution and performance of this Agreement have been duly authorized by all necessary
corporate actions. 
 8.5 Patentability, Infringement. CWRU makes no representation or warranties of any kind other than those of this
Article VIII including but not limited to warranties of patentability, merchantability or fitness for a particular purpose. 
 8.6 CWRU
represents that to the best of its knowledge, CWRU owns all right, title and interest in and to Existing Patent Rights and that all Investigators will be obligated to assign all right, title and interest in and to Technology and Developed Patent
Rights to CWRU. 

  
 7 

 ARTICLE IX: MISCELLANEOUS 

9.1 Indemnification. 
 (a)
OSIRIS will defend, indemnify and hold CWRU harmless from any loss, cost, damage, liability or expense imposed, on CWRU as a result of any third party claim arising from OSIRIS’ use, application or marketing of any Product or Process arising
from this Agreement. 
 (b) CWRU will defend, indemnify and hold OSIRIS harmless from any loss, cost, damage, liability or expense imposed on
OSIRIS as a result of any claim arising from CWRU’s breach of any term or provision of this Agreement. 
 (c) The party to be
indemnified shall promptly notify the indemnifying party of any claim to be indemnified. The indemnifying party shall have the right to control the defense, settlement or compromise of any claim. 

9.2 Insurance. OSIRIS shall not commence selling on a commercial basis of any Products in connection with this License until it has
obtained for itself or for CWRU at its own cost or special arrangements and expense, comprehensive general liability and products liability insurance with limits of at least $3,000,000 per occurrence/$3,000,000 aggregate, and naming CWRU as
additional insured. Upon the start of human clinical trials of any Product OSIRIS shall obtain comprehensive general liability insurance in accordance with the foregoing. Such insurance shall be provided by insurers of recognized responsibility and
well-rated by national organizations, and each policy shall state that the insurer will not terminate it or significantly reduce coverage without giving CWRU at least forty-five (45) days prior written notice. The product liability insurance
shall provide worldwide coverage and shall be on an “occurrence” basis. If such insurance is not available when OSIRIS is ready to commence human clinical trials or selling Products, CWRU agrees to waive the insurance requirement until
such insurance becomes available if and only if OSIRIS has and maintains a net worth of at least $3,000,000 as determined by a review of OSIRIS’ books conducted at OSIRIS’ expense by an independent firm of certified public accountants
mutually satisfactory to CWRU and OSIRIS. After the initial review, CWRU may have further reviews conducted from time to time, but not more than once each year. 

9.3 Sublicense. OSIRIS shall require all of its sublicensees hereunder to indemnify and hold harmless CWRU under the same terms as
stated in Section 9.1(a) and to carry comprehensive general liability insurance and product liability insurance with limits of at least $3,000,000 per occurrence/$3,000,000 aggregate naming CWRU as an additional insured under the same terms as
Section 9.2. 
 9.4 Independent Contractors. OSIRIS and CWRU are independent contractors, and neither shall have any
responsibility for the work performed by or on behalf of the other except to the extent expressly set forth in this Agreement. 
 9.5 Use
of Name. OSIRIS will not use the name of CWRU, related schools or departments in any publication or marketing materials without the written consent of CWRU. CWRU will not use the name of OSIRIS in any publication or marketing materials without
the written consent of OSIRIS. 

  
 8 

 9.6 Assignment. This Agreement is not assignable or transferable except with the written
consent of both parties; consent will not be withheld unreasonably, except that OSIRIS without the consent of CWRU may assign this Agreement to an Affiliate or to a transferee of all or substantially all of the portion of the business to which this
Agreement relates. Any such assignee or transferee of OSIRIS’ interest shall expressly assume in writing the performance of all of the terms and conditions of this Agreement to be performed by OSIRIS and such assignment shall not relieve OSIRIS
of any of its obligations under this Agreement. Any assignment or transfer without such consent or covered by such exception shall be void. 

9.7 Registration. OSIRIS agrees to register this Agreement when required by local or federal law and to pay all costs and legal fees
connected with such registration. 
 9.8 Successors and Assigns. The terms and provisions of this Agreement shall inure to the benefit
of and be binding upon the respective successors, permitted assigns and legal representatives of the parties hereto. 
 9.9 Choice of
Law. This Agreement shall be governed by and construed In accordance with the laws of the State of Ohio, excluding that body of law applicable to choice of law. 

9.10 Headings. The headings and captions used in this Agreement do not form part of this Agreement, but are included solely for
convenience. 
 9.11 Notices. All notices required or permitted under this Agreement shall be given in writing and shall be deemed
effectively given upon personal delivery to the party to be notified or five (5) days after deposit with the United States Postal Service, by registered or certified mall, postage prepaid and addressed to the party to be notified at the address
indicated for such party below, or at such other address as such party may designate by ten (10) days prior notice to the other party hereto: 
  

			
	If to OSIRIS: Copy to:		Copy to:
		
	 OSIRIS Therapeutics, Inc.
 11000 Cedar
Avenue
 Cleveland, Ohio 44106
 Attn: President
		 Elliot M. Olstein, Esq.
 Carella, Byrne, Bain,
Gilfillan,
 Cecchi & Stewart
 6 Becker Farm Road

Roseland, New Jersey 07068

		
	  
 If to CWRU:

 
 Dean of Graduate Studies and Research

Case Western Reserve University
 2040 Adelbert Road

Cleveland, Ohio 44106
		

  
 9 

 9.12 Amendments and Waivers. No waiver, amendment or modification of this Agreement will
be effective unless in writing and signed by both parties. 
 9.13 Illegality. If any term or condition of this Agreement is contrary
to applicable law, that term or condition will not apply and will not invalidate any other part of this Agreement. However, if its deletion materially and adversely changes the position of either of the parties, the affected party may terminate the
Agreement by giving thirty (30) days written notice. 
 9.14 Entire Agreement. This Agreement constitutes the entire
understanding and agreement of the parties hereto with respect to the subject matter hereof and supersedes all prior discussions, understandings and agreements with respect thereto. 

ARTICLE X: DEFINITIONS 

10.1 Technology. The term “Technology” shall mean any and all existing or future information, technical data, inventions,
discoveries or know-how, and materials whether or not patented or patentable, related to or useful for the identification, isolation, purification, propagation or use of mesenchymal stem cells and/or cells or products derived from or produced by
mesenchymal stem cells, which are conceived, developed or reduced to practice by an Investigator during the term of this Agreement while performing research at CWRU. 

10.2 Product(s). The term “Product(s)” shall mean any article, composition, apparatus, substance, chemical, material, method
or service which is, incorporates or utilizes Technology or the use, manufacture, import or sale of which is covered by a claim of any patent licensed hereunder. 

10.3 Process(es). The term “Process(es)” shall mean any process or method for the production, manufacture or use of any
Product or which is covered by any patent licensed hereunder. 
 10.4 The term “Affiliate” as applied to OSIRIS shall mean any
company or other legal entity other than OSIRIS in whatever country organized, controlling, or controlled by or under common control with OSIRIS. The term “control” means possession, direct or indirect, of the powers to direct or cause the
direction of the management and policies whether through the ownership of voting securities, by contract or otherwise. 
 10.5 Principal
Investigator. The term “Principal Investigator” shall mean either or both of Drs. Arnold I. Caplan and Stephen E. Haynesworth 

10.6 Material. The term “Material(s)” shall mean any material, biologic, or substance, which is Technology, including but not
limited to, cells, cell lines, vectors, antibodies, DNA (RNA) sequences, libraries, plasmids, cytokines, peptides, and proteins, which is discovered, produced or derived by an Investigator during the term of this Agreement. 

10.7 Investigator. The term “Investigator” shall mean Principal Investigators, any other member of CWRU staff, graduate
student, undergraduate student or employee of CWRU who works with or under the direction of a Principal Investigator. 

  
 10 

 10.8 “Existing Patent Rights” shall mean (i) A Method for Isolating, Purifying and
Culturally Expanding Marrow-Derived Mesenchymal Cells (U.S. Patent Application No. 615,430) ; (ii) Monoclonal Antibodies Specific for Marrow-Derived Mesenchymal Cells (U.S. Patent Application No. 716,917); (iii) A Method and
Device for Enhancing the Implantation and Differentiation of Marrow-Derived Mesenchymal Cells (U.S. Patent Application No. 614,915); and (iv) A Method and Device for Treating Connective Tissue Disorders (U.S. Patent Application
No. 614,912); any division, continuation, or continuation-in-part thereof and any foreign patent application or equivalent corresponding thereto and any Letters Patent or the equivalent thereof in any country of the world issuing thereon or
reissue or reexamination or extension thereof. 
 10.9 “Developed Patent Rights” shall mean any and all patents and patent
applications anywhere in the world which contains one or more claims directed to Technology, which is not an Existing Patent Right. 

  
 11 

 IN WITNESS WHEREOF, the undersigned parties have executed this Agreement on the dates indicated
below: 
  

									
	CWRU:		 		OSIRIS:
	FOR CASE WESTERN RESERVE				FOR OSIRIS THERAPEUTICS, INC.
	UNIVERSITY:				
			
	 /s/ R. James Henderson
				 /s/ James S. Burns

	Name:		R. James Henderson				Name:		James S. Burns
	Title:		VP Finance & Administration				Title:		President
	Date:		March 25, 1993				Date:		March 30, 1993

  
 12 

 Appendix A 

OSIRIS THERAPEUTICS, INC. 

Founders & Case Western Reserve University Capitalization 

 

																			
	FOUNDING SCIENTISTS*	 	  	FOUNDERS	 
	Shareholder	  	Shares	 	  	%	 	  	Shareholder	  	Shares	 	  	%	 
	 Arnold I. Caplan
	  	 	15,600	  	  	 	65.0	  	  	 Arnold I. Caplan
	  	 	15,600	  	  	 	55.7	  
	 Victor M. Goldberg
	  	 	6,720	  	  	 	28.0	  	  	 Victor M. Goldberg
	  	 	6,720	  	  	 	24.0	  
	 S. E. Haynesworth
	  	 	1,68	  	  	 	7.0	  	  	 S. E. Haynesworth
	  	 	1,680	  	  	 	6.0	  
		  				  				  	 Case Western R.U.
	  	 	1,200	  	  	 	4.3	  
		  	  
	  
	 	  	  
	  
	 	  	 James S. Bums
	  	 	2,800	  	  	 	10.0	  
	 TOTAL
	  	 	24,000	  	  	 	100.0	  	  		  	 	28,000	  	  	 	100.0	  

  

	*	Case Western Reserve University (“CWRU”) purchases 1 ,200 shares of Osiris Therapeutics, Inc. Common Stock at a price of $0.10 per share, equivalent to 5.0% of the Common Stock issued to the Company’s
three founding scientists (the “Founding Scientists”). Upon issuance of shares of Osiris Common Stock to Case Western Reserve University, the Founding Scientists and CWRU will together constitute the Company’s founders (collectively,
the “Founders”). 

	**	James S. Burns, the Company’s Chairman, President & Chief Executive Officer has purchased 2,800 shares of Osiris Common Stock on the same basis as the Founders in exchange for funding the Company’s
initial working capital requirements. The CEO’s and Founders’ Common Stock will together constitute the Company’s founding shareholders prior to the sale of additional shares to key employees, advisors, or investors in the
Company’s Initial Capitalization.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00250-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00250-of-00352.parquet"}]]